Idetrexed

Idetrexed (ONX 0801) is a thymidylate synthase (TS) inhibitor with a Ki of 1.2 nM. Idetrexed can be specifically transported into α-folate receptor (α-FR) -overexpressing tumors, such as ovarian cancer[1][2].

Product Specifications

CAS Number

[501332-69-0]

Product Name Alternative

BGC 945; ONX-0801; CB 300945

UNSPSC

12352005

Target

Thymidylate Synthase

Type

Reference compound

Related Pathways

Apoptosis

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/idetrexed.html

Solubility

10 mM in DMSO

Smiles

C#CCN(C1=CC=C(C=C1)C(N[C@H](C(O)=O)CCC(N[C@@H](C(O)=O)CCC(O)=O)=O)=O)[C@@H]2C3=CC(C(N=C(N4)CO)=O)=C4C=C3CC2

Molecular Formula

C32H33N5O10

Molecular Weight

647.63

References & Citations

[1]Gibbs DD, Theti DS, Wood N, Green M, Raynaud F, Valenti M, Forster MD, Mitchell F, Bavetsias V, Henderson E, Jackman AL. BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors. Cancer Res. 2005 Dec 15;65 (24) :11721-8.|[2]Tochowicz A, Dalziel S, Eidam O, O'Connell JD 3rd, Griner S, Finer-Moore JS, Stroud RM. Development and binding mode assessment of N-[4-[2-propyn-1-yl[ (6S) -4,6,7,8-tetrahydro-2- (hydroxymethyl) -4-oxo-3H-cyclopenta[g]quinazolin-6-yl]amino]benzoyl]-l-γ-glutamyl-D-glutamic acid (BGC 945), a novel thymidylate synthase inhibitor that targets tumor cells. J Med Chem. 2013 Jul 11;56 (13) :5446-55.